Karyopharm Therapeutics Inc. (KPTI)

Karyopharm Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	60.54	62.48	52.23	135.19	190.46
Short-Term Investments	3.2	46.24	139.21	142.78	38.16
Cash & Short-Term Investments	63.74	108.71	191.44	277.97	228.62
Cash Growth	-41.36%	-43.21%	-31.13%	21.59%	-8.28%
Accounts Receivable	26.18	30.77	26.96	47.09	22.5
Inventory	4.04	4.74	3.04	4.22	4.11
Other Current Assets	9.19	12.25	12.47	20.89	20.39
Total Current Assets	103.15	156.46	233.92	350.16	275.61
Net Property, Plant & Equipment	4.65	6.28	4.88	7.38	9.56
Other Long-Term Assets	0.62	1.67	1.64	0.63	20.14
Total Assets	108.42	164.42	240.44	358.17	305.31
Accounts Payable	4	5.11	3.12	2.77	1.6
Accrued Expenses	64.5	60.65	61.39	58.42	69.12
Current Portion of Long-Term Debt	21.01	24.43	-	-	-
Current Portion of Leases	0.97	0.44	3.31	2.87	2.32
Other Current Liabilities	1.58	1.64	1.65	1.85	0.68
Total Current Liabilities	92.06	92.26	69.48	65.91	73.72
Long-Term Debt	278.22	236.45	303.4	302.82	302.29
Long-Term Leases	5.74	6.71	2.79	6.1	8.97
Other Long-Term Liabilities	25.32	15.01	0.98	-	-
Total Long-Term Liabilities	309.28	258.17	307.17	308.92	311.26
Total Liabilities	401.34	350.44	376.64	374.83	384.98
Shareholders' Equity	-292.93	-186.02	-136.21	-16.66	-79.67
Total Liabilities & Equity	108.42	164.42	240.44	358.17	305.31
Total Debt	305.95	268.02	309.5	311.79	313.58
Net Cash (Debt)	-242.2	-159.31	-118.05	-33.83	-84.96
Net Cash Per Share	-22.15	-18.84	-15.50	-6.20	-16.94
Book Value	-292.93	-186.02	-136.21	-16.66	-79.67
Book Value Per Share	-26.79	-22.00	-17.88	-3.05	-15.89
Tangible Book Value	-292.93	-186.02	-136.21	-16.66	-79.67
Tangible Book Value Per Share	-26.79	-22.00	-17.88	-3.05	-15.89

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q